Abstract
The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
Keywords: Human, LINE-1, L1 element, retrotransposon, cancer, biomarker, detection, screening techniques, genome, remnants, reverse transcriptase, junk DNA, polymorphism, mutagenesis, anticancer therapy
Current Molecular Medicine
Title: The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Volume: 11 Issue: 4
Author(s): O. Piskareva, W. Lackington, D. Lemass, C. Hendrick, P. Doolan and N. Barron
Affiliation:
Keywords: Human, LINE-1, L1 element, retrotransposon, cancer, biomarker, detection, screening techniques, genome, remnants, reverse transcriptase, junk DNA, polymorphism, mutagenesis, anticancer therapy
Abstract: The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
Export Options
About this article
Cite this article as:
Piskareva O., Lackington W., Lemass D., Hendrick C., Doolan P. and Barron N., The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions, Current Molecular Medicine 2011; 11 (4) . https://dx.doi.org/10.2174/156652411795677954
DOI https://dx.doi.org/10.2174/156652411795677954 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Nimesulide and Its Analogues in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Pharmacogenomics of COPD
Current Pharmacogenomics Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam
Pharmaceutical Nanotechnology Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Imaging with Raman Spectroscopy
Current Pharmaceutical Biotechnology Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Bioremediation of Toxic Heavy Metals: A Patent Review
Recent Patents on Biotechnology Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review
Current Cancer Drug Targets Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry